Dr. Rudnicki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4301 W Markham St # 783
Little Rock, AR 72205Phone+1 501-686-8000
Education & Training
- UMass Chan Medical SchoolResidency, Neurology, 1982 - 1986
- Pennsylvania State University College of MedicineClass of 1982
Certifications & Licensure
- AR State Medical License 1992 - 2025
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Publications & Presentations
PubMed
- 53 citationsParaneoplastic syndromes of the spinal cord, nerve, and muscle.Stacy A. Rudnicki, Josep Dalmau
Muscle & Nerve. 2000-12-01 - 18 citationsReldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.Stacy A. Rudnicki, Jinsy A. Andrews, Tina Duong, Bettina M. Cockroft, Fady I. Malik
Neurotherapeutics. 2021-02-23 - 23 citationsRacial differences in motor neuron disease.Betul Gundogdu, Tawfiq Al-Lahham, Fred F. Kadlubar, Horace J. Spencer, Stacy A. Rudnicki
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2014-03-03
Other
- Initial treatment of dermatomyositis and polymyositis in adultsRudnicki SA, Miller ML
http://www.uptodate.com/contents/initial-treatment-of-dermatomyositis-and-polymyositis-in-adults
UpToDate, Wolters Kluwer Health - 2012-11-05 - Treatment of recurrent and resistant dermatomyositis and polymyositis in adultsRudnicki SA, Miller ML
http://www.uptodate.com/contents/treatment-of-recurrent-and-resistant-dermatomyositis-and-polymyosit
UpToDate, Wolters Kluwer Health - 2013-04-12
Press Mentions
- Cytokinetics Announces Five Presentations at the International Symposium on ALS/MNDNovember 26th, 2018
- Cytokinetics Announces Presentations at the Cure SMA 2017 Annual SMA ConferenceDecember 1st, 2017
- Cytokinetics Announces Baseline Data from First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients with SMAJuly 5th, 2017
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: